Wyant Simboli

Psivant Therapeutics?Launch Psivant is advancing a paradigm shift in biotechnology by pioneering a physics + AI approach to drug design that is tightly coupled to chemistry and biology research and development. As corporate story/branding partner for Psivant, Wyant Simboli welcomed the opportunity to articulate Psivant’s groundbreaking science, collaborative culture and commitment to developing medicines for patients in need. ? Wyant Simboli worked closely with Psivant CEO,?Woody Sherman, to create a new company name, corporate identity and develop the brand story and corporate website to express how Psivant is applying its computational physics + AI approach to develop better therapeutics, atom by atom. Psivant is enjoying an enthusiastic response to its launch. Investors and other key audiences appreciate the impact of Psivant’s vibrant brand identity, which is tightly aligned with the company’s industry-leading science, and the vitality of its multi-disciplinary team of experts in physics, computer-aided drug design, chemistry and structural biology.

https://lnkd.in/eafA8Bam

Thank you America's Blood Centers, CEO Kate Fry, MBA, CAE and outgoing president Robert Van Tuyle for hosting an excellent capstone event on Capitol Hill for the recent ABC Annual Meeting. Fantastic to meet so many passionate transfusion medicine professionals, advocates and legislators. The passion to #savelives exhibited by recipients such as James Harrison https://n.pr/41sFdtw are shared by the @Cellphire Therapeutics, Inc. team. Thank you for including us!

The superstar duo from TandemAI will also unveil the first superbly engineered, real-time, pocket-based AI chemistry assistant designed specifically for precision drug design. #Copilot #AIinDrugDiscovery #ComputationalChemistry #MolecularVisualization #TandemSandbox #DrugDiscovery #Webinar

I am looking forward to moderating a panel at the Quantum Convergence conference next Tuesday, March 11, at The Engine Accelerator in Cambridge, MA. Quantum Computing (QC) is one of the most exciting frontiers in technology, but when will it really impact drug discovery? That’s the central question I’ll be tackling as I moderate the panel: "How (and When) Quantum Computing Will Change the Life Sciences Landscape in Massachusetts" with panelists Namshik Han (KURE.ai) and Gopal Karemore (IBM). The promise of quantum computing in drug discovery is undeniable—but so are the challenges. Despite impressive advancements, current quantum computers have yet to outperform classical methods in solving real-world drug discovery problems. This panel isn’t about hype—it’s about realism. We’ll assess where quantum computing stands today, how it fits into drug discovery pipelines, and what needs to happen before it can make a meaningful impact in life sciences. Here are some of the challenges that I see (we will only have time to cover a subset in this panel). 1) Hardware Limitations: More Qubits, Less Noise * Qubit Quality – Today’s quantum computers suffer from high error rates due to noise and decoherence. Current qubits are fragile and easily disturbed by their environment. * Scalability – We will likely need millions of qubits to achieve fault-tolerant quantum computing for drug discovery, yet the largest machines today only have hundreds of noisy qubits. * Error Correction – Quantum error correction (QEC) is essential, but current QEC techniques require many additional physical qubits per logical qubit, making it inefficient. 2) Finding Practical Use Cases * Quantum Advantage vs. Classical Supremacy * Algorithm Development * Hybrid Approaches 3) Software & Infrastructure * Programming Complexity * Lack of Standardization * Quantum Simulation vs. Real Hardware 4) Practical Implementation & Cost * Cryogenic Cooling & Power Requirements * Cost & Commercial Viability * Industry Adoption 5) Fundamental Physics & Theoretical Limits * Decoherence & Quantum Noise * Quantum-Classical Transition * Beyond Today's Qubits (alternative approaches such as topological qubits, neutral atoms, and photonic quantum computing are promising but remain largely experimental) While hype often outpaces reality, quantum computing remains one of the most promising frontiers in technology. The big question isn’t if it will be useful—it’s when and how we’ll unlock its full potential. If you’re interested in the future of computational chemistry, AI, and quantum technologies in drug discovery, I hope to see you there! Other folks you will see include Larissa Bifano, Steven Dickman, and Andrea de Souza. Learn more here: https://lnkd.in/et6EqKwe #QuantumComputing #DrugDiscovery #ComputationalChemistry #AI #Biotech #Pharma #QuantumConvergence

?? Happy to share the recording of our engaging fireside chat: The Past, Present, and Future of In Silico Drug Discovery ?? David Pearlman and I had the opportunity to sit together on Friday and discuss the evolution of computational drug discovery—where we've been, where we are, and where we're headed. John F. Conway was an excellent moderator -- thanks John! We explored how AI, physics-based modeling, and scalable software solutions are reshaping drug discovery, while also acknowledging the critical role of human expertise, experimental validation, and critical gaps. Some key themes we covered: *** Drug Discovery as a Team Sport *** -Why success in drug discovery depends on building the right interdisciplinary team (not just computational) -The evolution of computational chemistry and its major inflection points -Why drug discovery needs more scalable software to reduce reliance on bespoke, human-dependent processes *** Technology, AI, and Data *** -The impact of DeepMind and public datasets (PDB, etc.) on computational chemistry -How free energy calculations and force fields have advanced over time -The promise and challenges of generative AI in drug design *** Complexity in Biology and Future Directions *** -The limitations of current models in capturing real biological complexity -Empirical vs. physics-based approaches—where do we draw the line? -The challenges of assay development and reproducibility -Balancing AI’s potential with realistic expectations for drug discovery -The field is moving fast, and [AI + physics] are playing a bigger role than ever—but there are still major hurdles to overcome. If you missed the discussion, you can watch the recording here: https://lnkd.in/gYSDRxXr Let’s keep the conversation going! What do you think will be the biggest breakthrough in computational drug discovery in the next five years? #DrugDiscovery #ComputationalChemistry #AI #MachineLearning #CADD #GenerativeAI #Biotech #Pharma

New BioBoss podcast https://lnkd.in/dBsiuJwe featuring Vlad Vitoc, MD, MBA, founder and CEO of MAIA Biotechnology, Inc.. Hear Vlad speak with BioBoss host and Wyant Simboli principal John Simboli about leadership in biopharma and how MAIA is working to develop and deliver innovative medicines to improve and extend the lives of people living with cancer. #BioBoss, #leadership, #innovation, #entrepreneurship, #biopharma, #biotech, #technology, #lifescience, #cancer

Rallybio, through our joint venture, is developing REV102, an ENPP1 inhibitor for the treatment of hypophosphatasia (HPP).?? ? REV102 aims to restore bone health by reducing levels of inorganic pyrophosphate. We expect to report data from a preclinical model of later-onset HPP in 2H25 and start a Phase 1 study in 2026. #Rallybio #REV102 #HPP #RareDiseases #Biotech #RLYB Click this link to learn more: https://lnkd.in/eX8JgyWa

We’re thrilled to share that Cellphire Therapeutics has reached a major milestone in our Phase 2/3 CRYPTICS clinical study! This achievement is a testament to the dedication of our team, the support of our partners, and the potential of platelet-based technology to improve patient outcomes. Thank you to everyone who has contributed to this journey! Stay tuned as we continue to push the boundaries of science and innovation. Read more: https://lnkd.in/eRpsQqt4 #Cellphire #Biotech #ClinicalTrials #Innovation #Healthcare #PlateletTechnology

I am really happy to announce our collaboration between Acellera Therapeutics and Psivant Therapeutics to push the frontiers of AI-driven drug discovery! Together, we are integrating quantum chemistry, machine learning, and agentic AI to revolutionize how small-molecule therapeutics are discovered and optimized. This partnership is more than just a technological challenge—it’s a shared vision. I have immense appreciation for Woody Sherman and the Psivant team. Together, we are moving into a new generation of engineering drugs and we’re just getting started! #AI #MolecularReasoning #QuantumChemistry #DrugDiscovery Read the press release here: https://lnkd.in/dfgm6BSX